Effect of zenarestat, an aldose reductase inhibitor, on endoneurial blood flow in experimental diabetic neuropathy of rat

Neurosci Lett. 2001 Sep 14;310(2-3):81-4. doi: 10.1016/s0304-3940(01)02052-3.

Abstract

The effects of zenarestat, an aldose reductase inhibitor, on endoneurial blood flow (NBF) were explored in streptozotocin-induced diabetic rats. Rats were maintained on a diet of containing 0.09% zenarestat for 8 weeks, then NBF in the sciatic nerve was measured using microelectrode hydrogen polarography. NBF in the diabetic control rats was significantly lower than values in age-matched control rats, however, NBF was not significantly altered in diabetic rats treated with zenarestat. Direct application of nitric oxide synthase inhibitor, NG-nitro-L-arginine, did not affect NBF in diabetic control rats, whereas this application significantly reduced NBF both in age-matched control and zenarestat treated diabetic rats. Considerable levels of zenarestat were confirmed in the sciatic nerve in the drug treated rats. These data suggest that aldose reductase, such as zenarestat, might restore or prevent the alteration of endoneurial blood flow resulting from an impairment of nitric oxide function.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aldehyde Reductase / antagonists & inhibitors*
  • Animals
  • Diabetic Neuropathies / drug therapy*
  • Diabetic Neuropathies / metabolism
  • Enzyme Inhibitors / pharmacology*
  • Hydrogen / pharmacokinetics
  • Male
  • Microelectrodes
  • Nitric Oxide / metabolism
  • Nitroarginine / pharmacology
  • Peripheral Nerves / blood supply*
  • Peripheral Nerves / enzymology
  • Quinazolines / pharmacology*
  • Rats
  • Rats, Sprague-Dawley
  • Regional Blood Flow / drug effects
  • Sciatic Nerve / blood supply
  • Sciatic Nerve / enzymology

Substances

  • Enzyme Inhibitors
  • Quinazolines
  • FR 74366
  • Nitroarginine
  • Nitric Oxide
  • Hydrogen
  • Aldehyde Reductase